A. Michael Lincoff, MD

Appointed
1991

Education & Fellowships

Fellowship - Cleveland Clinic
Interventional Cardiology
Cleveland, OH United States
1993

Fellowship - Cleveland Clinic
Cardiovascular Disease
Cleveland, OH United States
1992

Fellowship - University of Michigan Health System
Cardiovascular Medicine
Ann Arbor, MI
1991

Residency - Beth Israel Deaconess Medical Center and Harvard Medical School
Internal Medicine
Boston, MA
1989

Internship - Beth Israel Deaconess Medical Center and Harvard Medical School
Medical Internship
Boston, MA
1987

Medical Education - Johns Hopkins University School of Medicine
Baltimore, MD
1986

Undergraduate - Carnegie Mellon University
Chemical/Biomed. Engineering
Pittsburgh, PA
1982

Professional Highlights

• Director, Center for Clinical Research and Vice Chairman for Clinical Research of the Cleveland Clinic Lerner Research Institute
• Director, Cleveland Clinic Coordinating Center for Clinical Research (C5Research)
• Vice Chairman, Department of Cardiovascular Medicine, Cleveland Clinic
• Charles and Charlotte Fowler Endowed Chair in Cardiovascular Research, Cleveland Clinic

Certifications

• Internal Medicine - Interventional Cardiology
• Internal Medicine - Cardiovascular Disease
• Internal Medicine

Specialty Interests

Coronary artery disease, heart attack, stent restenosis, angioplasty, rotational atherectomy, stent-coronary, coronary artery atherectomy, coronary intervention, drug eluting stenting

Awards & Honors

• Best Doctors, Cleveland magazine

Memberships

• American College of Cardiology
• European Society of Cardiology
• American College of Physicians
• American Heart Association
• Sigma Xi Research Society

See publications for A. Michael Lincoff, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 4/19/2024, Dr. Lincoff has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Lincoff receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• i2o Therapeutics, Inc.
• Medscape
• Recor Medical
• Alnylam Pharmaceuticals, Inc.
• Brainstorm Cell Therapeutics
• Novo Nordisk, A/S
• Eli Lilly and Company
• Medtronic plc

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.